mounjaro glp 1 GLP-1 use tripled among non-diabetics, reaching $5.8B in 2022 The Mounjaro Diet: A Complete
Description
An elevated resting heart rate can increase long-term cardiovascular risk, and regulators need robust data confirming that the metabolic benefits outweigh this potential downside
Sitagliptin decreases the LPS-inflammatory response by inhibiting the NF-kB pathway
Healthier populations lead to fewer sick days, higher workforce participation, and reduced long-term healthcare costs
Some studies have also documented improvements in markers of endothelial dysfunction and oxidative stress, processes intimately linked with vascular inflammation
